For purposes of this practice management guideline, review articles were classified as class III. Reviewers also determined whether the respective article was relevant to the purpose of the practice management guidelines. Nineteen studies were determined to be nonrelevant and were excluded from further analysis; nonrelevance was based on the following: poor methodology (11) , inadequate study size (6) , and irrelevant purpose (2) .
The remaining 27 articles were used to construct an evidentiary table, which was analyzed to make final recommendations. Recommendations were classified based on the quality of scientific evidence available:
Level I: recommendation is justifiable based on the available scientific evidence alone; recommendation is based on class I or a preponderance of class II evidence. Level II: recommendation is reasonably justifiable based on the available scientific evidence and supported by expert opinion; recommendation is supported by class II evidence or a preponderance of class III evidence. Level III: recommendation is supported by available data, but inadequate scientific data are available; recommendation is supported by class III evidence. 
RECOMMENDATIONS

SCIENTIFIC FOUNDATION
In 1998, Luchette et al. 3 presented the results of the EAST Practice Management Guidelines Workgroup at the 11th Annual Scientific Assembly. These guidelines were published in 2000 on the EAST Web site. Based on a review of 54 articles published from 1975 to 1997, the workgroup offered three level I and two level II recommendations specific to choice of antibiotic coverage and duration of therapy. The original guidelines recommend preoperative dosing with antibiotics as soon as possible after the injury has been sustained. Antibiotics should be directed at gram-positive organisms with additional gram-negative coverage for type III fractures. In the presence of potential clostridial contamination, penicillin should also be initiated irrespective of fracture type.
With regard to duration of antibiotic coverage, the original guidelines recommend that antibiotics be discontinued 24 hours after successful wound closure for type I and type II fractures. For type III fractures, antibiotics should be continued for 72 hours subsequent to the injury or not Ͼ24 hours subsequent to successful soft tissue coverage of the wound.
In 1999, DeLong et al. 6 published a case series designed to compare rates of infection as well as delayed union and nonunion in patients with open fractures based on the type of wound closure performed. Ninety patients with 119 open fractures were reviewed. All patients received cefazolin plus gentamicin if severe contamination was identified. Antibiotics were discontinued 2 days to 3 days after the last surgical procedure. By using this antibiotic regimen, the rate of deep wound infection or osteomyelitis was 7% irrespective of the wound management technique. In a prospective study of 227 patients with open fractures, Vasenius et al. compared clindamycin with cloxacillin. Clindamycin was demonstrated to be effective in type I and type II fractures with infection rates of 3.3% and 1.8%, respectively. Unacceptably high rates of infection were reported in grade III fractures for both clindamycin (29.0%) and cloxacillin (51.8%). This study demonstrates the efficacy of gram-positive coverage for types I and II fractures and confirms the need for additional gram-negative coverage in higher Gustilo type fractures. 7 In a study of pediatric patients with open forearm fractures, Greenbaum et al. 8 
Citing several advantages of fluoroquinolones (e.g., oral administration, less nephrotoxicity), Patzakis et al. performed a prospective study of intravenous ciprofloxacin in 163 patients with 171 open fractures: type I (65), type II (54), and type III (52). Patients were randomized to an antibiotic regimen of ciprofloxacin or ceftazadime/gentamicin. In types I and II fractures, the infection rate for the ciprofloxacin group and the ceftazadime/gentamicin group was 5.8% and 6.0%, respectively. For type III fractures, an unacceptably high rate of infection was demonstrated in the ciprofloxacin group (31%) compared with the ceftazadime/ gentamicin group (7.7%). 10 In response to a clinical observation that delayed union and nonunion were associated with ciprofloxacin, Huddleston et al. published a laboratory investigation of the effect of this fluoroquinolone on fracture healing. Wistar rats with experimentally induced femur fractures were randomized to receive cefazolin and ciprofloxacin. A third group that received no antibiotics was used as a control group. Radiographic, histologic, and mechanical parameters all demonstrated inhibition of fracture healing in the ciprofloxacin group. 11 Similarly, using a murine model, Holtom et al. 12 demonstrated a dose-dependent cytotoxic effect of fluoroquinolones.
In 1999, Sorger et al. published a study comparing the efficacy of once-daily dosing of aminoglycosides with the traditional divided-dose regimen. Two hundred nineteen patients with type II or type III open fractures all received standard surgical treatment of their fractures. All patients received cefazolin but were randomized to receive gentamicin in divided-dose regimen (5 mg/kg divided twice daily) or once-daily (6 mg/kg). Although a statistical difference could not be demonstrated, infection rate in the once-daily patients was lower than in the patients receiving divided dose (6.7% vs. 13.6%). 13 In a preliminary study, Russel et al. 14 
SUMMARY
Based on a review of the literature published subsequent to their original presentation, the recommendations published in the original EAST guidelines remain valid. Antibiotics are an important adjunct to the management of 
FUTURE INVESTIGATION
The available class I literature on fluoroquinolones has several limitations. Not all studies used an open fracture model. In addition, as these were animal studies, dosages and duration of therapy may not be equivalent to that which may be used clinically. Therefore, given the significant advantages of this class of antibiotics over aminoglycosides, research should continue in an effort to demonstrate efficacy in a clinical model. The systemic side effects of antibiotics may also be reduced through the use of local antibiotic therapy. Future research should also consider the use of this modality in the acute phase of open fracture management.
potential morbidity from renal failure resulting from aminoglycosides is likely to be more significant.
The literature does not provide strong guidance for prophylactic antibiotic choice in penicillin-allergic patients. It is likely that vancomycin is the appropriate prophylactic antibiotic for gram-positive coverage of open fractures in these patients.
In summary, this review provides evidence-based guidelines for prophylactic antibiotics in treating open fractures. We commend the authors for their valuable contribution to physician education and patient care.
